Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0%

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 3,330,000 shares, an increase of 37.0% from the August 31st total of 2,430,000 shares. Based on an average trading volume of 261,900 shares, the short-interest ratio is presently 12.7 days. Approximately 15.7% of the company's stock are sold short.

Wall Street Analysts Forecast Growth

• Analysts are Upgrading These 3 Stocks…Here’s Why

Several research firms recently commented on PRLD. JMP Securities reissued a "market outperform" rating and set a $7.00 target price on shares of Prelude Therapeutics in a research note on Monday, September 16th. HC Wainwright upgraded shares of Prelude Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 19th. Finally, Barclays downgraded shares of Prelude Therapeutics from an "equal weight" rating to an "underweight" rating and set a $3.00 price objective on the stock. in a research report on Thursday, June 20th.

Get Our Latest Stock Report on Prelude Therapeutics

Institutional Investors Weigh In On Prelude Therapeutics

Several institutional investors have recently modified their holdings of PRLD. Acadian Asset Management LLC increased its stake in shares of Prelude Therapeutics by 42.7% during the 1st quarter. Acadian Asset Management LLC now owns 22,110 shares of the company's stock worth $104,000 after purchasing an additional 6,615 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Prelude Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company's stock worth $4,821,000 after purchasing an additional 10,143 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Prelude Therapeutics by 2.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company's stock worth $1,990,000 after purchasing an additional 14,226 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Prelude Therapeutics by 103.2% in the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company's stock valued at $111,000 after purchasing an additional 14,769 shares during the period. Finally, Kennedy Capital Management LLC acquired a new position in Prelude Therapeutics in the first quarter valued at $119,000. Hedge funds and other institutional investors own 79.72% of the company's stock.

Prelude Therapeutics Price Performance

Shares of NASDAQ:PRLD traded down $0.09 on Friday, reaching $2.12. The company's stock had a trading volume of 119,234 shares, compared to its average volume of 471,009. Prelude Therapeutics has a 52-week low of $1.66 and a 52-week high of $6.80. The stock has a market capitalization of $116.64 million, a P/E ratio of -1.13 and a beta of 1.52. The stock's 50-day moving average is $4.75 and its two-hundred day moving average is $4.39.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.46). Equities analysts forecast that Prelude Therapeutics will post -1.85 earnings per share for the current fiscal year.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.

Featured Stories

• Five stocks we like better than Prelude Therapeutics
• Utilities Stocks Explained – How and Why to Invest in Utilities
• Simon Property REIT: A Safe Bet for Growth and Steady Dividends
• How to Choose Top Rated Stocks
• CarMax’s Impressive Rally: What Investors Should Watch Next
• What is the NASDAQ Stock Exchange?
• MarketBeat Week in Review – 9/23 - 9/27

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ It’s over. (From Behind the Markets) (Ad)

Should you invest $1,000 in Prelude Therapeutics right now?

Before you consider Prelude Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.

While Prelude Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here